Skip to main content
Clinical Trials/NCT05115552
NCT05115552Not yet recruitingNot Applicable

Comparison Between Urocortin 2 and Brain Type Natriuretic Peptide as a Biomarker in Patients With Acute Heart Failure

Assiut University0 sites60 target enrollmentStarted: November 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
60
Primary Endpoint
Assessment of the clinical utility of urocortin 2 in monitoring AHF patients

Study Overview

Brief Summary

  1. Evaluation of the role of serum urocortin 2 levels in acute decompensated HF patients and their association with clinical and echocardiographic findings.
  2. Assessment of the clinical utility of urocortin 2 in monitoring AHF patients.
  3. Comparison between urocortin 2 and BNP as a biomarker in AHF patients

Detailed Description

Heart failure (HF) is a clinical syndrome with symptoms and/or signs caused by a structural and/ or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion. (1) .The pathophysiology of HF is a complex interplay of genetic and multiple molecular mechanisms (from inflammation to hormonal pathways) performing in the composite network of the cardiovascular system environment. (2).

Monitoring of biomarkers in HF can be used to make an initial diagnosis, to aid in prognostic stratification, and to identify a patient's response to therapeutic intervention. (3).

Natriuretic peptide (NP) concentrations are quantitative plasma biomarkers for the presence and severity of haemo-dynamic cardiac stress and heart failure. (4). That facilitate renal filtration and sodium excretion whilst suppressing the vasoconstrictor sodium, retaining Renin angiotensin aldosterone system and exerting a tonic anti-trophic effect. (5). But the natriuretic peptide levels are significantly affected by weight, the NT- proBNP in obese subjects is much lower than normal weight subjects. (6). Other factors that affect BNP levels including gender, age and renal disease

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients with acute decompensated heart failure.

Exclusion Criteria

  • Acute coronary syndrome or stroke in the past 3 months.
  • Severe chronic kidney disease.
  • Severe valve disease.

Outcomes

Primary Outcomes

Assessment of the clinical utility of urocortin 2 in monitoring AHF patients

Time Frame: baseline

Evaluation of the role of serum urocortin 2 levels

Time Frame: baseline

Evaluation of the role of serum urocortin 2 levels in acute decompensated HF patients and their association with clinical and echocardiographic findings.

Secondary Outcomes

  • Comparison between urocortin 2 and BNP(baseline)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Christen Saad Welliam

resident

Assiut University

Similar Trials